Identification of New KRAS G12D Inhibitors through Computer-Aided Drug Discovery Methods

Owing to several mutations, the oncogene Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is activated in the majority of cancers, and targeting it has been pharmacologically challenging. In this study, using an in silico approach comprised of pharmacophore modeling, molecular docking, and molecu...

Descripción completa

Detalles Bibliográficos
Autores principales: Kulkarni, Apoorva M., Kumar, Vikas, Parate, Shraddha, Lee, Gihwan, Yoon, Sanghwa, Lee, Keun Woo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8836163/
https://www.ncbi.nlm.nih.gov/pubmed/35163234
http://dx.doi.org/10.3390/ijms23031309

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8836163/
https://www.ncbi.nlm.nih.gov/pubmed/35163234
http://dx.doi.org/10.3390/ijms23031309

Ejemplares similares